Release issued 15th March 2001

CLIMEST® Dot is a very small patch developed by Ethical Pharmaceuticals South America SA for continuous release of 17 beta-estradiol following application to the skin.

The Transdermal Delivery System is prepared to remain in place during a 4-day period. Transdermal products have the considerable advantages of offering a non-invasive parenteral route for drug therapy. In a bioavailability study carried out in postmenopausal women, CLIMEST® Dot, with an active area of 7 cm2, has shown to offer estradiol plasma levels similar to those reached with the administration of Vivelle Dot 50 mcg/day.

CLIMEST® Dot is mainly indicated for the treatment of moderate to severe symptoms associated with the menopausal syndrome; female hypogonadism or castration; primary ovarian failure; and atrophic conditions caused by deficient endogenous estrogen production, such as atrophic vaginitis and kraurosis vulvae.

CLIMEST® Dot has a very good adhesion to the skin and an excellent cosmetic aspect. Contact with water, as in bathing, does not affect the device. Ethical Pharmaceutical South America SA has a long experience in the design and development of transdermal systems; specially, those destined to hormonal replacement therapy.

CLIMEST® Dot is still available for license in certain territories.

Ethical Pharmaceuticals South America SA is an Argentinean company engaged in the development and licensing of transdermal and gel products under its proprietary technology.

(12th February 2005) Amarin Technologies SA, announces the approval of its Fentanyl TDS in Argentina.

(5th August 2004) Amarin Technologies Argentina announces a partnership agreement for its Fentanyl patch.

(27th September 2002) Amarin Technologies SA Launches a High Strength Diclofenac Gel

(11th December 2001) Amarin Corporation plc Announces Sale of Transdermal Patch Development Unit in Argentina

(6th April 2001) Amarin has developed an innovative Diclofenac TDS with systemic effects.